Therapeutic potential of adenosine receptor antagonists and agonists

Bibliography

• BELARDINELLI L, LINDEN J, BERNE RM: The cardiac effects of adenosine. Prog. Cardiovasc. Dis. (1989) 32:73-97.
   PubMed Web of Science ®Google Scholar
• BLACKBURN MR, LEE CG, YOUNG HW et al.: Adenosine mediates IL-13-induced inflammation and remodelling in the lung and interacts in an IL-13-adenosine amplification pathway. J. Clin. Invest. (2003) 112:332-344.
   PubMed Web of Science ®Google Scholar
• CHURCHILL PC: Renal effects of 2-chloroadenosine and their antagonism by aminophylline in anesthetized rats. J. Pharmacol. Exp. Ther. (1982) 222:319-323.
   PubMedGoogle Scholar
• FREDHOLM BB, DUNWIDDIE TV: How does adenosine inhibit transmitter release? Trends Pharmacol. Sci. (1988) 9:130-134.
   PubMed Web of Science ®Google Scholar
• HUANG S, APASOV S, KOSHIBA M et al.: Role of A2A extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood (1997) 90:1600-1610.
   PubMedGoogle Scholar
• OHTA A, SITKOVSKY M: Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature (2001) 414:916-920.
   PubMed Web of Science ®Google Scholar
• TILLEY SL, WAGONER VA, SALVATORE CA et al.: Adenosine and inosine increase cutaneous vasopermeability by activating A3 receptors on mast cells. J. Clin. Invest. (2000) 105:361-367.
   PubMed Web of Science ®Google Scholar
• BODANSKY O, SCHWARTZ MJ: 5′-Nucleotidase. Adv. Clin. Chem. (1968) 11:277-328.
   PubMedGoogle Scholar
• MENTZER RM, RUBIO R, BERNRE RM: Release of adenosine from hypoxic canine lung tissue and its possible role in the pulmonary circulation. Am. J. Physiol. (1975) 229:1625-1631.
   PubMed Web of Science ®Google Scholar
• ARCH JRS, NEWSHOLME EA: The control of the metabolism and the hormonal role of adenosine. Essays Biochem. (1978) 14:82-123.
   PubMedGoogle Scholar
• TRAMS EG, LAUTER CJ: On the sidedness of plasma membrane enzymes. Biochem. Biophys. Acta (1974) 345:180-197.
   PubMedGoogle Scholar
• FREDHOLM BB, IJZERMAN AP, JACOBSON KA, KLOZ K-N, LINDEN J: International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. (2001) 53:527-552.
   PubMed Web of Science ®Google Scholar
• FUXE K, FERRE S, CANALS M et al.: Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J. Mol. Neurosci. (2005) 26:209-220.
   PubMed Web of Science ®Google Scholar
• BURGUENO J, BLAKE D J, BENSON MA et al.: The adenosine A2A receptor interacts with the actin-binding protein α-actinin. J. Biol. Chem. (2003) 278:37545-37552.
   PubMedGoogle Scholar
• GSANDTNER I, CHARALAMBOUS C, STEFAN E, OGRIS E, FREISSMUTH M, ZEZULA J: Heterotrimeric G protein-independent signaling of a G protein-coupled receptor. Direct binding of ARNO/cytohesin-2 to the carboxyl terminus of the A2A adenosine receptor is necessary for sustained activation of the ERK/MAP kinase pathway. J. Biol. Chem. (2005) 280:31898-31905.
   PubMedGoogle Scholar
• MILOJEVIC T, REITERER V, STEFAN E et al.: The ubiquitin-specific protease Usp4 regulates the cell surface level of the A2A receptor. Mol. Pharmacol. (2006) 69:1083-1094.
   PubMed Web of Science ®Google Scholar
• SUN CN, CHENG HC, CHOU JL et al.: Rescue of p53 blockage by the A2A adenosine receptor via a novel interacting protein, translin-associated protein X. Mol. Pharmacol. (2006) 70:454-466.
   PubMed Web of Science ®Google Scholar
• LINDEN J: Adenosine in tissue protection and tissue regeneration. Mol. Pharmacol. (2005) 67:1385-1387.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, GAO Z-G: Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov. (2006) 5:247-264.
   PubMed Web of Science ®Google Scholar
• AKKARI R, BURBIEL JC, HOCKEMEYER J, MULLER CE: Recent progress in the development of adenosine receptor ligands as anti-inflammatory drugs. Curr. Top. Med. Chem. (2006) 6:1375-1399.
   PubMed Web of Science ®Google Scholar
• SITKOVSKY MV, OHTA A: The ‘danger’ sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol. (2005) 26:299-304.
   PubMed Web of Science ®Google Scholar
• XU Z, JANG Y, MUELLER RA, NORFLEET EA: IB-MECA and cardioprotection. Cardiovasc. Drug Rev. (2006) 24:227-238.
   PubMedGoogle Scholar
• HEADRICK JP, PEART J: A3 adenosine receptor-mediated protection of the ischemic heart. Vasc. Pharmacol. (2005) 42:271-279.
   PubMedGoogle Scholar
• ADAIR TH: Growth regulation of the vascular system: an emerging role for adenosine. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 289:R283-R296.
   PubMed Web of Science ®Google Scholar
• VARANI K, CARAMORI G, VINCENZI F et al.: Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2006) 173:398-406.
   PubMed Web of Science ®Google Scholar
• RUSSO C, ARCIDIACONO G, POLOSA R: Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthma. Fund. Clin. Pharm. (2006) 20:9-19.
   PubMedGoogle Scholar
• FEOKTISTOV I, POLOSA R, VOLGATE ST, BIAGGIONI I: Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol. Sci. (1998) 19:148-153.
   PubMedGoogle Scholar
• MERIGHI S, MIRANDOLA P, VARANI K et al.: A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol. Ther. (2003) 100:31-48.
   PubMed Web of Science ®Google Scholar
• LAW WR: Adenosine receptors in the response to sepsis: what do receptor-specific knockouts tell us. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2006) 291:R957-R958.
   Google Scholar
• AWAD AS, HUANG L, YE H et al.: Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. (2006) 290:F828-F837.
   PubMed Web of Science ®Google Scholar
• YANG H, AVILA M Y, PETERSON-YANTORNO K et al.: The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Curr. Eye Res. (2005) 30:747-754.
   PubMed Web of Science ®Google Scholar
• XU K, BASTIA E, SCHWARZSCHILD M: Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol. Ther. (2005) 105:267-310.
   PubMed Web of Science ®Google Scholar
• ELZEIN E, KALLA R, LI X et al.: N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists. Bioorg. Med. Chem. Lett. (2007) 17:161-166.
   PubMed Web of Science ®Google Scholar
• FATHOLAHI M, XIANG Y, WU Y et al.: A novel partial agonist of the A1-adenosine receptor and evidence of receptor homogeneity in adipocytes. J. Pharm. Exp. Ther. (2006) 317:676-684.
   PubMed Web of Science ®Google Scholar
• EGGEBRECHT H, GOSSL M: Regadenoson CV therapeutics/Astellas. Curr. Opin. Investig. Drugs (2006) 7:264-271.
   PubMed Web of Science ®Google Scholar
• LI Y, OSKOUIAN RJ, DAY Y-J et al.: Mouse spinal cord compression injury is reduced by either activation of the adenosine A2A receptor on bone marrow-derived cells or deletion of the A2A receptor on non-bone marrow-derived cells. Neuroscience (2006) 141:2029-2039.
   PubMed Web of Science ®Google Scholar
• CAVALCANTE IC, CASTRO MV, BARRETO ARF et al.: Effect of novel A2A agonist ATL313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect. Immun. (2006) 74:2606-2612.
   PubMed Web of Science ®Google Scholar
• MILLER D: Impact of selective adenosine A2A receptor agonists on cardiac imaging. J. Am. Coll. Card. (2005) 46:2076-2078.
   PubMedGoogle Scholar
• CERQUEIRA MD: The future of pharmacologic stress: selective A2A adenosine receptor agonists. Am. J. Card. (2004) 94(2A):D33-D42.
   PubMed Web of Science ®Google Scholar
• UDELSON JE, HELLER GV, WACKERS FJT et al.: Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging. Circulation (2004) 109:457-464.
   PubMed Web of Science ®Google Scholar
• MARTIN PL, BARRETT RJ, LINDEN J et al.: Pharmacology of 2-cyclohexylmethyl-idenehydrazinoadenosine (WRC-0470), a novel, short-acting adenosine A2A receptor agonist that produces selective coronary vasodilation. Drug Dev. Res. (1997) 40:313-324.
   Web of Science ®Google Scholar
• NEUSTADT B, HAO J, LINDO N et al.: Development of a selective, orally active adenosine A2A receptor antagonist for the treatment of Parkinson's disease: Sch 420814. Abstracts of Papers, 231st ACS National Meeting. Atlanta, GA, United States (26 – 30, March 2006) (2006):MEDI-204.
   Google Scholar
• PENG H, KUMARAVEL G, YAO G: Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists. J. Med. Chem. (2004) 47:6218-6229.
   PubMed Web of Science ®Google Scholar
• SUN CX, ZHONH H, MOHSENSIN A et al.: Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J. Clin. Investig. (2006) 116:2173-2182.
   PubMed Web of Science ®Google Scholar
• HARRISON C: Lung cancer: strengthening the link to adenosine. Nat. Rev. Drug Discov. (2006) 5:820-820.
   Google Scholar
• JACOBSON KA, KIM HO, SIDDIQI SM et al.: A3-adenosine receptors: design of selective ligands and therapeutic prospects. Drugs Fut. (1995) 20:689.
   PubMedGoogle Scholar
• NAHIR MA et al.: 69th Annu. Sci. Meet. Am. Coll. Rheumatol. San Diego (12 – 17 November 2005) (Abstract L7).
   Google Scholar
• FISHMAN P, COHN I, BAR-YEHUDA S et al.: Proc. Am. Assoc. Cancer Res. (AACR) (2004) 45:(Abstract LB-335).
   Google Scholar
• BARALDI PG, FRUTTAROLO F, TABRIZI MA et al.: Synthesis and biological evaluation of novel N6-[4-(substituted)sulfonamidophenylcarbamoyl]adenosine-5′-uronamides as A3 adenosine receptor agonists. J. Med. Chem. (2004) 47:5535-5540.
   PubMed Web of Science ®Google Scholar
• BARALDI PG, PRETI D, TABRIZI MA et al.: New pyrrolo[2,1-f] purine-2, 4-dione and imidazo[2,1-f] purine-2, 4-dione derivatives as potent and selective human A3 adenosine receptor antagonists. J. Med. Chem. (2005) 48:4697-4701.
   PubMedGoogle Scholar